Currently, HIF‐1 prolyl hydroxylase (PH) inhibitors, as a new generation of approved oral therapeutic agents for renal anaemia, correct anaemia by activating the HIF pathway and targeting the HIF pathway has become a therapeutic strategy for a wide range of diseases.40, 41. This evidence concerns the gene HIF1A and anemia.